Skip to main content

Advertisement

SpringerLink
Log in

Posttransplant cyclophosphamide beyond haploidentical transplantation

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Posttransplant cyclophosphamide (PTCy) has practically revolutionized haploidentical (Haplo) hematopoietic cell transplantation (HCT). Comparisons between Haplo with PTCy and unrelated donor (URD) with conventional graft-versus-host disease (GVHD) prophylaxis have shown comparable overall survival with lower incidences of GVHD with Haplo/PTCy and led to the following question: is it PTCy so good that can be successfully incorporated into matched related donor (MRD) and URD HCT? In this review, we discuss other ways of doing PTCy, PTCy in peripheral blood haploidentical transplants, PTCy in the context of matched related and matched unrelated donors, PTCy with mismatched unrelated donors, and PTCy following checkpoint inhibitor treatment. PTCy is emerging as a new standard GVHD prophylaxis in haploidentical, HLA-matched, and -mismatched HCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Luznik L, O’Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650. https://doi.org/10.1016/j.bbmt.2008.03.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF (2019) Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis. Biol Blood Marrow Transplant 25:2422–2430. https://doi.org/10.1016/j.bbmt.2019.07.028

    Article  CAS  PubMed  Google Scholar 

  3. Luznik L, Pasquini MC, Logan B et al (2022) Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. JCO 40:356–368. https://doi.org/10.1200/JCO.21.02293

    Article  CAS  Google Scholar 

  4. Zu Y, Li Z, Gui R et al (2022) Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Bone Marrow Transplant 57:1573–1580. https://doi.org/10.1038/s41409-022-01754-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bolaños-Meade J, Reshef R, Fraser R et al (2019) Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 6:e132–e143. https://doi.org/10.1016/S2352-3026(18)30221-7

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kanakry CG, O’Donnell PV, Furlong T et al (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JCO 32:3497–3505. https://doi.org/10.1200/JCO.2013.54.0625

    Article  CAS  Google Scholar 

  7. Moiseev IS, Pirogova OV, Alyanski AL et al (2016) Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant 22:1037–1042. https://doi.org/10.1016/j.bbmt.2016.03.004

    Article  CAS  PubMed  Google Scholar 

  8. Gooptu M, Romee R, St. Martin A et al (2021) HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood 138:273–282. https://doi.org/10.1182/blood.2021011281

  9. Brissot E, Labopin M, Moiseev I et al (2020) Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol 13:87. https://doi.org/10.1186/s13045-020-00923-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mehta RS, Saliba RM, Rondon G et al (2022) Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transplant Cell Ther 28:695.e1-695.e10. https://doi.org/10.1016/j.jtct.2022.07.021

    Article  CAS  PubMed  Google Scholar 

  11. Berro M, Rivas M, Trucco J et al (2021) Post-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experience. Bone Marrow Transplant 56:986–988. https://doi.org/10.1038/s41409-020-01146-0

    Article  CAS  PubMed  Google Scholar 

  12. Cooper DL, Manago J, Patel V et al (2021) Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study. Bone Marrow Transplant 56:1099–1105. https://doi.org/10.1038/s41409-020-01144-2

    Article  CAS  PubMed  Google Scholar 

  13. Holtan SG, Hamadani M, Wu J et al (2022) Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. Blood 140:LBA-4-LBA-4. https://doi.org/10.1182/blood-2022-171463

  14. Broers AEC, de Jong CN, Bakunina K et al (2022) Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv 6:3378–3385. https://doi.org/10.1182/bloodadvances.2021005847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brissot E, Lpobin M, Labussiere H et al (2021) POST-transplantation cyclophosphamide vs. antithymocyte globulin after ric regimen allo-hct: first analysis of a prospective randomized multicenter trial in recipients of 10/10 matched donors. Bone Marrow Transplant 56:12–13. https://doi.org/10.1038/s41409-021-01341-7

    Article  Google Scholar 

  16. Carnevale-Schianca F, Caravelli D, Gallo S et al (2021) Post-transplant cyclophosphamide and tacrolimus—mycophenolate mofetil combination governs GVHD and immunosuppression need, reducing late toxicities in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors. JCM 10:1173. https://doi.org/10.3390/jcm10061173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chevallier P, Le Bourgeois A, Garnier A et al (2021) A prospective phase 2 study testing high dose post-transplant cyclophosphamide as sole GHVD prophylaxis after matched allotransplant using Baltimore-based reduced-intensity conditioning regimens and PBSC as source of graft. Blood 138:1812–1812. https://doi.org/10.1182/blood-2021-149534

    Article  Google Scholar 

  18. Solomon SR, Sanacore M, Zhang X et al (2014) Calcineurin inhibitor–free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 20:1828–1834. https://doi.org/10.1016/j.bbmt.2014.07.020

    Article  CAS  PubMed  Google Scholar 

  19. Greco R, Lorentino F, Morelli M et al (2016) Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood 128:1528–1531. https://doi.org/10.1182/blood-2016-06-723205

    Article  CAS  PubMed  Google Scholar 

  20. Kunacheewa C, Owattanapanish W, Jirabanditsakul C, Issaragrisil S (2020) Post-transplant cyclophosphamide and thymoglobulin, a graft-versus-host disease prophylaxis in matched sibling donor peripheral blood stem cell transplantations. Cell Transplant 29:096368972096590. https://doi.org/10.1177/0963689720965900

    Article  Google Scholar 

  21. Spyridonidis A, Labopin M, Brissot E et al (2022) Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. https://doi.org/10.1038/s41409-022-01816-1

  22. Kwon M, Bailén R, Pascual-Cascón MJ et al (2019) Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Adv 3:3351–3359. https://doi.org/10.1182/bloodadvances.2019000236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Shaw BE, Jimenez-Jimenez AM, Burns LJ et al (2021) National marrow donor program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. JCO 39:1971–1982. https://doi.org/10.1200/JCO.20.03502

    Article  CAS  Google Scholar 

  24. Battipaglia G, Labopin M, Kröger N et al (2019) Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134:892–899. https://doi.org/10.1182/blood.2019000487

    Article  CAS  PubMed  Google Scholar 

  25. Jimenez Jimenez A, Komanduri K, Brown S et al (2022) Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv 6:4491–4500. https://doi.org/10.1182/bloodadvances.2022007596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Modi D, Kondrat K, Kim S et al (2021) Post-transplant cyclophosphamide versus thymoglobulin in hla-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome. Transplant Cell Ther 27:760–767. https://doi.org/10.1016/j.jtct.2021.06.018

    Article  CAS  PubMed  Google Scholar 

  27. Mehta RS, Saliba RM, Hayase E et al (2022) Mycophenolate mofetil: a friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors? Transplant Cell Ther 28:500.e1-500.e10. https://doi.org/10.1016/j.jtct.2022.05.039

    Article  CAS  PubMed  Google Scholar 

  28. Koura D, Tzachanis D, Ball ED et al (2021) A randomized phase II trial comparing a calcineurin inhibitor-free graft-versus-host disease prophylaxis regimen with post-transplantation cyclophosphamide and abatacept to standard of care. Blood 138:1816–1816. https://doi.org/10.1182/blood-2021-145824

    Article  Google Scholar 

  29. Bejanyan N, Pidala JA, Wang X et al (2021) A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv 5:1154–1163. https://doi.org/10.1182/bloodadvances.2020003779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Battipaglia G, Labopin M, Blaise D et al (2022) Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther 28:587.e1-587.e7. https://doi.org/10.1016/j.jtct.2022.06.006

    Article  CAS  PubMed  Google Scholar 

  31. Zhang W, Gui R, Zu Y et al (2022) Reduced‐dose post‐transplant cyclophosphamide plus low‐dose post‐transplant anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis with fludarabine–busulfan–cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: a multicentre, randomized controlled clinical trial. Br J Haematol. https://doi.org/10.1111/bjh.18483

  32. Chiusolo P, Bug G, Olivieri A et al (2018) A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transplant 24:1243–1249. https://doi.org/10.1016/j.bbmt.2018.01.031

    Article  CAS  PubMed  Google Scholar 

  33. Lazzari L, Balaguer-Roselló A, Montoro J et al (2022) Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 57:1389–1398. https://doi.org/10.1038/s41409-022-01725-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. McAdams MJ, Hyder M, Dimitrova D et al (2021) Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood 138:101–101. https://doi.org/10.1182/blood-2021-146997

    Article  Google Scholar 

  35. Sugita J, Kamimura T, Ishikawa T et al (2021) Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 56:596–604. https://doi.org/10.1038/s41409-020-01065-0

    Article  CAS  PubMed  Google Scholar 

  36. Duléry R, Goudet C, Mannina D et al (2022) Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. https://doi.org/10.1038/s41409-022-01908-y

    Article  PubMed  PubMed Central  Google Scholar 

  37. Al-Homsi AS, Roy TS, Cole K et al (2015) Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 21:604–611. https://doi.org/10.1016/j.bbmt.2014.08.014

    Article  CAS  PubMed  Google Scholar 

  38. Strauss G, Osen W, Debatin K-M (2002) Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128:255–266. https://doi.org/10.1046/j.1365-2249.2002.01777.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kanakry CG, Ganguly S, Zahurak M et al (2013) Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 5. https://doi.org/10.1126/scitranslmed.3006960

  40. Kanakry CG, Coffey DG, Towlerton AMH et al (2016) Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 1. https://doi.org/10.1172/jci.insight.86252

  41. Arcuri LJ, Hamerschlak N, Rocha V et al (2021) Outcomes after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide: a systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimens and bone marrow with peripheral blood stem cell grafts. Transplant Cell Ther 27:782.e1-782.e7. https://doi.org/10.1016/j.jtct.2021.06.011

    Article  CAS  PubMed  Google Scholar 

  42. Salas MQ, Prem S, Remberger M et al (2020) High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma 61:3198–3208. https://doi.org/10.1080/10428194.2020.1797010

    Article  CAS  PubMed  Google Scholar 

  43. Kanakry CG, Bolaños-Meade J, Kasamon YL et al (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389–1393. https://doi.org/10.1182/blood-2016-09-737825

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Holtick U, Chemnitz J-M, Shimabukuro-Vornhagen A et al (2016) OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol 96:27–35. https://doi.org/10.1111/ejh.12541

    Article  CAS  PubMed  Google Scholar 

  45. Salas MQ, Atenafu EG, Law AD et al (2021) Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leuk Lymphoma 62:3373–3383. https://doi.org/10.1080/10428194.2021.1966781

    Article  CAS  PubMed  Google Scholar 

  46. on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH), Bailén R, Kwon M et al (2021) Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol 100:541–553. https://doi.org/10.1007/s00277-020-04317-7

  47. O’Donnell PV, Luznik L, Jones RJ et al (2002) Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8:377–386. https://doi.org/10.1053/bbmt.2002.v8.pm12171484

    Article  PubMed  Google Scholar 

  48. Goldsmith SR, Abid MB, Auletta JJ et al (2021) Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 137:3291–3305. https://doi.org/10.1182/blood.2020009362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Solán L, Landete E, Bailén R et al (2020) Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. Hematol Oncol 38:597–603. https://doi.org/10.1002/hon.2772

    Article  CAS  PubMed  Google Scholar 

  50. Oltolini C, Greco R, Galli L et al (2020) Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching. Biol Blood Marrow Transplant 26:1179–1188. https://doi.org/10.1016/j.bbmt.2020.01.013

    Article  PubMed  Google Scholar 

  51. Kumar K, Subash C, Prabhu D et al (2021) Experience of low dose (25mg/Kg) of cyclophosphamide (Chennai-Chezhian-Kishore PTCy Protocol) as post transplant cyclophosphamide (PTCy) dose in haploidentical bone marrow transplant. Blood 138:4867–4867. https://doi.org/10.1182/blood-2021-144784

    Article  Google Scholar 

  52. Bobillo S, Nieto JC, Barba P (2021) Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. Bone Marrow Transplant 56:1784–1793. https://doi.org/10.1038/s41409-021-01268-z

    Article  PubMed  Google Scholar 

  53. Schoch LK, Cooke KR, Wagner-Johnston ND et al (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226–2229. https://doi.org/10.1182/bloodadvances.2018019208

    Article  PubMed  PubMed Central  Google Scholar 

  54. Paul S, Zahurak M, Luznik L et al (2020) Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic hodgkin lymphoma: a retrospective cohort study. Biol Blood Marrow Transplant 26:1679–1688. https://doi.org/10.1016/j.bbmt.2020.06.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Oran B, Garcia-Manero G, Saliba RM et al (2020) Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126:2193–2205. https://doi.org/10.1002/cncr.32796

    Article  CAS  PubMed  Google Scholar 

  56. Saberian C, Abdel-Wahab N, Abudayyeh A et al (2021) Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9:e001818. https://doi.org/10.1136/jitc-2020-001818

  57. Nikoloudis A, Buxhofer-Ausch V, Aichinger C et al (2023) Adverse impact of a high CD4 / CD8 ratio in the allograft may be overcome by methotrexate- but not mycophenolate- or post-transplant cyclophosphamide-based graft versus host disease prophylaxis. Eur J Haematol 110:715–724. https://doi.org/10.1111/ejh.13956

    Article  CAS  PubMed  Google Scholar 

  58. Clausen J, Böhm A, Straßl I et al (2017) HLA-C KIR-ligands determine the impact of anti-thymocyte globulin (ATG) on graft versus host and graft versus leukemia effects following hematopoietic stem cell transplantation. Biomedicines 5:13. https://doi.org/10.3390/biomedicines5020013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Research Organization, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701, São Paulo, SP, 05652-900, Brazil

    Leonardo Javier Arcuri

  2. Bone Marrow Transplantation Unit, Insituto Nacional de Cancer, Rio de Janeiro, Brazil

    Leonardo Javier Arcuri

  3. Bone Marrow Transplantation Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil

    Andreza Alice Feitosa Ribeiro, Nelson Hamerschlak & Mariana Nassif Kerbauy

Authors
  1. Leonardo Javier Arcuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreza Alice Feitosa Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nelson Hamerschlak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariana Nassif Kerbauy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors participated in the design of the manuscript. LJA and MNK wrote the manuscript. All authors critically reviewed the manuscript and approved the submission.

Corresponding author

Correspondence to Leonardo Javier Arcuri.

Ethics declarations

Ethics approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arcuri, L.J., Ribeiro, A.A.F., Hamerschlak, N. et al. Posttransplant cyclophosphamide beyond haploidentical transplantation. Ann Hematol 103, 1483–1491 (2024). https://doi.org/10.1007/s00277-023-05300-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05300-8

Keywords

Search

Navigation